2-(2-苯基乙氧基)乙醇 | 74121-91-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(2-苯基乙氧基)乙醇
• 英文名称: 2-phenethyloxyethanol
• 英文别名: 2-phenethoxyethan-1-ol；2-(2-Phenylethoxy)ethanol
• CAS: 74121-91-8
• 化学式: C₁₀H₁₄O₂
• 分子量: 166.22
• InChiKey: KMZPWWIVZVTDRT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(2-苯基乙氧基)乙醇 在 palladium on activated charcoal 盐酸 、 氢气 、 硝酸 、 sodium carbonate 、 sodium nitrite 作用下， 以 乙醇 为溶剂， 反应 3.33h， 生成 4-<2-(2-hydroxyethoxy)ethyl>benzonitrile
  参考文献：
  名称：

  .beta.1-Selective adrenoceptor antagonists. 2. 4-Ether-linked phenoxypropanolamines

  摘要：

  A series of 4-substituted phenoxypropanolamines was prepared and examined for beta-adrenoceptor activity. Some of the compounds, especially the [4-[2-[[2-(4-fluorophenyl)ethyl] oxy]ethoxy]phenoxy]propanolamines (14, 15, and 24), showed potent beta 1-blockade with virtually no beta 2-blockade at doses over a 1000 times greater. The compounds also possessed partial agonist activity. Structure-activity relationships are discussed, and conclusions are drawn about the binding sites on beta-adrenoceptors.

  DOI：

  10.1021/jm00365a005
• 作为产物：
  描述：

  苯乙醇 在 lithium aluminium tetrahydride 、 sodium hydride 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 6.0h， 生成 2-(2-苯基乙氧基)乙醇
  参考文献：
  名称：

  使用碱基不稳定保护基团自动逐步合成 PEG

  摘要：

  使用定制的修饰肽合成仪和具有碱不稳定保护基团的单体实现了聚乙二醇 (PEG) 的自动逐步合成。含有酸不稳定对甲氧基苄基接头的 Wang 树脂用作固体支持物。将含有甲苯磺酰基离去基团和碱不稳定苯乙基保护基团的PEG 5衍生物TsOPEG 5 O(CH 2 ) 2 Ph用作单体。通过对位的去质子化进行 PEG 的自动组装Wang树脂上的-甲氧基苯甲醇，然后在第一个循环中与单体反应。随后的循环包括在碱性条件下苯乙基基团的去保护，以及在弱碱性条件下与单体直接偶联。脱保护得到 PEG 作为醇盐，这使得与单体的直接偶联成为可能。不需要单独的去质子化步骤。中间体和产物的纯化通过洗涤树脂简单地实现。在所有步骤中，材料被加入和从合成器软件控制的反应容器中移除。在合成结束时，PEG n O(CH 2 ) 2 Ph 产物用 TFA 从树脂上裂解下来。使用自动化方法，高质量的单分散 PEG合成了10 O(CH 2

  DOI：

  10.1016/j.tet.2022.132861

文献信息

• Aliphatic amino bis-aryl squalene synthase inhibitors
  申请人：Rhone-Poulenc Rorer Pharmaceuticals Inc.

  公开号：US05455260A1

  公开（公告）日：1995-10-03

  This invention relates to a class of novel aliphatic amino bis-aryl compounds containing at least four carbon atoms and an amino group either substituted thereon or incorporated therein and is further linked or bridged to two mono- and/or bicyclic rings. Compounds of this invention reduce levels of serum cholesterol in the body without significantly reducing mevalonic metabolite synthesis. This invention relates also to pharmacological compositions and method of treatment for lowering serum cholesterol levels using the compounds of this invention.

  这项发明涉及一类新型的脂肪族氨基双芳基化合物，其中至少含有四个碳原子和一个氨基团，该氨基团可以被取代或者内含，并且进一步连接或者桥接到两个单环和/或双环环。这项发明的化合物在不显著降低麦角甾醇代谢产物合成的情况下，降低体内血清胆固醇水平。这项发明还涉及使用这些化合物降低血清胆固醇水平的药理组合物和治疗方法。
• PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF
  申请人：MIURA Tomoya

  公开号：US20130085132A1

  公开（公告）日：2013-04-04

  The present invention provides a pyrazole compound of the following general Formula [Ib] having SGLT1 inhibitory activity, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and its pharmaceutical use: wherein each symbol is the same as defined in the description.

  本发明提供了一种具有SGLT1抑制活性的下式[Ib]所示的吡唑化合物、或其药物可接受的盐、包含该化合物的药物组合物及其医药用途： 其中每个符号如说明书中所定义。
• Generation of Alkoxyl Radicals by Photoredox Catalysis Enables Selective C(sp³ )−H Functionalization under Mild Reaction Conditions
  作者：Jing Zhang、Yang Li、Fuyuan Zhang、Chenchen Hu、Yiyun Chen

  DOI：10.1002/anie.201510014

  日期：2016.1.26

  Reported herein is the first visible‐light‐induced formation of alkoxyl radicals from N‐alkoxyphthalimides, and the Hantzsch ester as the reductant is crucial for the reaction. The selective hydrogen atom abstraction by the alkoxyl radical enables C(sp3)−H allylation and alkenylation reactions under mild reaction conditions at room temperature. Broad substrate variations, including a structurally complexed

  本文报道的是由N-烷氧基邻苯二甲酰亚胺形成的第一个可见光诱导的烷氧基自由基，汉茨酯作为还原剂对反应至关重要。烷氧基自由基对氢原子的选择性提取使C（sp 3）-H烯丙基化和烯基化反应在室温下温和的反应条件下进行。广泛的底物变化，包括结构复杂的类固醇，均能有效进行C（sp 3）-H官能化反应，并具有较高的区域选择性和化学选择性。
• [EN] NOVEL ETHER LINKED COMPOUNDS AND IMPROVED TREATMENTS FOR CARDIAC AND CARDIOVASCULAR DISEASE<br/>[FR] NOUVEAUX COMPOSÉS À LIAISON ÉTHER ET TRAITEMENTS AMÉLIORÉS POUR LA MALADIE CARDIAQUE ET CARDIOVASCULAIRE
  申请人：UNIV NOTTINGHAM

  公开号：WO2012104659A1

  公开（公告）日：2012-08-09

  A compound of Formula (I), and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: wherein R1 is independently selected from F, CI, Br, CN, NH2, OH, CHO, COOH, oxo, C1-4alkyl, C1-4alkoxy, CONH2 (optionally mono- or di-substituted by C1-4alkyl) and SO2NH2, R2 is independently selected from C1-6allkyl substituted by R3 wherein the C1-6alkyl chain optionally comprises one or two heteroatoms select from O; R3 is selected from aryl, C3-6cycloalkyl, C3-6heterocyclyl and C3-6heteroaryl, wherein the heterocyclyl and heteroaryl rings are nitrogen containing; and wherein R3 is optonally substituted by one or more groups selected from R1; n1 is zero or an integer from 1 to 2; n2 is an integer from 1 to 2; and the sum of n1 and 2 is less than or equal to 2; R5 is selected from any group defined for R1 and R2; R6a and R6b are independently selected from H or C1-4alkyl; R7 is independently selected from F, CI, Br, CN, NH2, OH, CHO, COOH, oxo, C1-4alkyl, C1-4alkoxy, CONH2 (optionally mono- or di-substituted by C1-4alkyl) and SO2NH2, Q1, Q2 and Q3 are independently selected from H or any group defined for R1 and R2; or Q1 and Q2 or Q2 and Q3 together form a C5-6heteroaryl or C5-6heterocylclic ring; optionally containing one or two heteroatoms selected from N and O optionally substituted by any group selected from R5; Z is selected from linear C2-3 alkylene; X3 is O; X4 is selected from aryl, a 9-10 membered heteroaryl ring or a 9-10 membered heterocyclic ring, wherein the heteroaryl and heterocyclic rings contain one or more heteroatoms selected from N, and optionally additionally O, and wherein X4 is optionally substituted by one or two oxo moieties and is optionally substituted by one or more groups selected from R7; with the proviso that: (i) when X4 is phenyl then Q1 and Q2 or Q2 and Q3-together form an optionally substituted heteroaryl or heterocylclic ring as defined above; and (ii) when Q1, Q2 and Q3 are independently selected from H or any group defined for R1 and R2 then X4 is not phenyl except when R2 is C1-5alkyl substituted by R3 wherein R3 is C3-6heterocyclyl as defined above.

  公式（I）的化合物及其在自由形式或盐形式中的药学上可接受的盐或可生理水解的衍生物：其中R1独立选择自F、Cl、Br、CN、NH2、OH、CHO、COOH、oxo、C1-4烷基、C1-4烷氧基、CONH2（可选地经C1-4烷基单取代或双取代）和SO2NH2，R2独立选择自由R3取代的C1-6烷基，其中C1-6烷基链可选地包括从O中选择的一个或两个杂原子；R3选择自芳基、C3-6环烷基、C3-6杂环烷基和C3-6杂芳基，其中杂环烷基和杂芳基环含氮；其中R3可选地由R1中选择的一个或多个基团取代；n1为零或1至2的整数；n2为1至2的整数；n1和2的和小于或等于2；R5选择自定义为R1和R2的任何基团；R6a和R6b独立选择自H或C1-4烷基；R7独立选择自F、Cl、Br、CN、NH2、OH、CHO、COOH、oxo、C1-4烷基、C1-4烷氧基、CONH2（可选地经C1-4烷基单取代或双取代）和SO2NH2，Q1、Q2和Q3独立选择自H或自定义为R1和R2的任何基团；或Q1和Q2或Q2和Q3一起形成C5-6杂芳基或C5-6杂环状环；可选地含有从N和O中选择的一个或两个杂原子，可选地由R5中选择的任何基团取代；Z选择自线性C2-3烷基；X3为O；X4选择自芳基、9-10成员杂芳基环或9-10成员杂环状环，其中杂芳基和杂环状环含有从N中选择的一个或多个杂原子，可选地另外含有O，X4可选地由一个或两个oxo基团取代，并可选地由R7中选择的一个或多个基团取代；但条件是：（i）当X4为苯基时，Q1和Q2或Q2和Q3一起形成如上定义的可选取代的杂芳基或杂环状环；和（ii）当Q1、Q2和Q3独立选择自H或自定义为R1和R2的任何基团时，X4不是苯基，除非R2为由R3取代的C1-5烷基，其中R3如上所定义为C3-6杂环烷基。
• [EN] DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA)<br/>[FR] BÊTA-LACTONES DISUBSTITUÉS EN TANT QU'INHIBITEURS DE L'AMIDASE ACIDE DE N-ACYLÉTHANOLAMINE (NAAA)
  申请人：UNIV CALIFORNIA

  公开号：WO2013078430A1

  公开（公告）日：2013-05-30

  The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

  本发明提供了用于抑制N-酰乙醇胺酸酰胺酶（NAAA）的化合物和药物组合物。考虑到抑制NAAA是一种维持棕榈酰乙醇胺（PEA）和油酰乙醇胺（OEA）水平的方法，这两种物质是NAAA的底物，在特征为PEA和OEA浓度降低的情况下。该发明还提供了治疗炎症性疾病和疼痛以及其他与降低PEA和OEA水平相关的疾病的方法。